Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of Anatomical and Functional Outcomes with Ocriplasmin in Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
2014-004778-41Phase 4Terminated
- Sponsor
- Alcon Inc.
- Start
- Jun 2015
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ocriplasmin in vitreomacular traction (VMT) and vitreomacular adhesion (VMA), sponsored by Alcon Inc. Primary endpoint: Proportion of subjects with nonsurgical resolution of focal VMT/sVMA. Started Jun 2015; status: terminated.
02
Drugs
ocriplasmin
03
Conditions
vitreomacular traction (VMT)vitreomacular adhesion (VMA)
Beyond the preview
Go deeper on 2014-004778-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004778-41.